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This thematic series of Harm Reduction Journal explores
the issues surrounding the current state of tobacco harm
reduction at global and local levels. Tobacco harm reduc-
tion (THR) refers to strategies designed to reduce the
health risks associated with tobacco smoking but which
may involve the continued use of nicotine. The health con-
sequences of tobacco smoking are well documented; if
current trends continue, it has been estimated that globally,
a billion lives will be lost to tobacco smoking in the
twenty-first century [1]. However, although some countries
have embraced the concept, THR has not been, and is not,
widely accepted or implemented, with heavy sanctions on
reduced risk nicotine-containing products (including
e-cigarettes, snus and heat not burn products) in many
countries. Mike Russell famously stated ‘smokers smoke for
the nicotine, but die from the tar’ [2]. Despite the ringing
clarity of this message that it is the thousands of toxicants
and numerous carcinogens in tobacco smoke that leads to
premature death and disease, many years on, the science of
‘cleaner’ nicotine-containing products remains heavily con-
tested. Nicotine’s long association with combustible tobacco
continues to mar social political dialect surrounding the
use of nicotine products for harm reduction.
Quitting smoking is a difficult process; high rates of re-
lapse are testament to this. For example, 6–12-month ab-
stinence rates with no intervention are only around 3%,
with an estimated percentage point increase of between 6
and 15% with nicotine replacement therapy (NRT), bupro-
prion or varenicline [3]. NRT may not adequately assist
with all of the symptoms of smoking withdrawal, and for
many more it is not an adequate long-term smoking re-
placement. E-cigarettes address the behavioural aspects of
smoking in addition to providing nicotine and are now the
most preferred method of quitting smoking [4]. However,
when highlighting the potential of e-cigarettes for smoking
cessation, in the absence of supporting empirical evidence,
it is important not to overstate their achievements com-
pared to NRT [5].
Although there is emerging evidence for their effective-
ness as a smoking cessation aid, many smokers continue to
smoke alongside e-cigarette use [6–9], or report that
e-cigarettes are not a satisfying alternative to smoking [10].
Moreover, smoking prevalence remains disproportionately
high in underrepresented (e.g. vulnerable/marginalised)
groups (estimates of above 80% in those dependence on
illicit substances) [11], and the effectiveness of e-cigarettes
and other reduced risk nicotine-containing products have
not been extensively researched in these groups. While so
many smokers are still attached to smoking, more choice
and availability of a range of both medicinal and consumer
reduced risk nicotine-containing products is needed includ-
ing NRT, e-cigarettes, snus, heat not burn products along
with a greater understanding of how products may comple-
ment each other.
The development and maintenance of smoking is under-
pinned by a multifaceted and often complex set of interact-
ing biopsychosocial issues, not captured by one theory.
Experts in substance use know this. Despite this knowledge,
one of the most commonly cited objections to reduced risk
products is that because they contain nicotine they may act
as a so-called gateway to regular cigarette smoking for
non-smokers. However, one featured study shows that
regular e-cigarette use is almost exclusive to ex and current
smokers [9]. While this and other studies may help to
counter claims of ‘gateway’ theories, this study along with
past research shows that dual-use (i.e. use of an e-cigarette
and smoking) is high. Why smokers with access to reduced
risk products would still want to smoke and what factors
encourage complete to switching to reduced harm products
are key areas requiring empirical investigation.
Exploring quitting trajectories (which are presented in
this issue) through qualitative research provides a more
nuanced approach to understanding individual differences
in smoking cessation. At a local level (which this thematic
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series invites), the narratives of those averse to change,
those who have changed and those who have failed to
switch, elucidate the challenges of behaviour change and
also how nationwide strategies are perceived.
This edition features timely reminders of why the wider
public perception of nicotine is so often skewed and marred
by its association with tobacco [12]. Indeed, despite an
emerging reduced risk market, public perception around
the risks of these products is often inaccurate and the num-
ber of people incorrectly believing that e-cigarettes are as
harmful or more harmful than smoking seems to be in-
creasing [7]. This issue features one article which highlights
how systems of communicating harms of smokeless to-
bacco originated and may continue to pollute the messa-
ging of other nicotine-containing products. Tobacco health
warning labels and risk-related messages have received a
great deal of empirical attention in relation to their persua-
sive impact on driving down levels of smoking. With the
landscape of nicotine use changing regulation has not kept
up, messages on cigarettes appear to have been ‘borrowed’
and adapted, perhaps inappropriately, for use on much less
harmful products. Despite these changes, the unintended
consequences of warning labels on smokers’ perceptions of
reduced risk products remain an emerging field.
Understanding the conditions under which smokers
switch to e-cigarettes or other reduced risk products
is clearly a priority area for research but one that
may be exclusive to countries where regulation is re-
laxed, markets are developing and real world user be-
haviour can contribute to scientific evidence. The
bigger picture is that there are still many countries
with extremely high smoking prevalence rates with
little or no access to reduced risk products. Where
THR goes from here is unclear and is dependent on
many factors. Perceptions and tolerance of nicotine
vary widely between countries. Selective reporting,
misrepresentation and/or misunderstanding of evi-
dence further muddy the water. This may be com-
pounded by a distrust of the tobacco industry and
scepticism over its involvement and role in harm re-
duction. Nevertheless, opposition to harm reduction
and tensions that exist between the scientific, industry
and political communities on the issue of e-cigarettes
and other reduced risk products ultimately means
users lose out.
While the evidence on the reduced harm status of
e-cigarettes, snus and other non-combustible
nicotine-containing products continues to accumulate,
there are those who continue to focus on the uncertainties.
Tobacco harm reduction, although not risk free, is likely to
reap considerable public health benefits but for its potential
to be realised, a paradigm shift is required; there is no place
for intolerance to nicotine per se when smoking-related
death and disease continue unabated across the globe.
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